Publication | Closed Access

Erythropoietin and long-acting erythropoiesis stimulating agent ameliorate non-alcoholic fatty liver disease by increasing lipolysis and decreasing lipogenesis via EPOR/STAT pathway

InflammationObesityMetabolic SyndromeLong-acting ErythropoiesisHepatologyMedicineLiver PhysiologyPathologyFatty Liver DiseasePharmacologyAtherosclerosisLipid SynthesisEpor/stat PathwayHealth Sciences